MiR-199a targeting ROCK1 to affect kidney cell proliferation, invasion and apoptosis
Source abstract
Abstract
Renal cell carcinoma (RCC) is one of the three most common cancers of urinary tract cancer, accounting for 2-3% of all systemic cancers. Recent studies have found that miR-199a is lowly expressed in RCC, may act as a tumour suppressor gene to induce the occurrence of kidney cancer. In the present study, we investigated the role of miR-199a in the progression and metastasis of RCC. The results showed that miR-199a significantly downregulated in RCC and cell lines. Overexpression of miR-199a in RCC cell lines significantly inhibited cell proliferation, migration and invasion. Furthermore, the qRT-PCR and western blot results showed that miR-199a overexpression significantly downregulated ROCK-1 mRNA and protein levels. ROCK1 was identified as a target of miR-199a, and ectopic expression of miR-199a downregulated ROCK1 by direct binding to its 3' untranslated region. Together, these findings indicate that miR-199a acts as a tumour suppressor and its downregulation in tumour tissues may contribute to the progression and metastasis of RCC through a mechanism involving ROCK1, suggesting miR-199a as a potential new diagnostic and therapeutic target for the treatment of RCC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Global Maritime and Colonial Histories · Historical and Linguistic Studies · African history and culture analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China;
Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China;
Department of Nephrology, The Affiliated Hospital of Shao Yang University, Shaoyang, China;
Department of Nephrology, Xiangya Hospital Central South University, Changsha, China
References (24)
Show source-provided references
1. 10.3109/21691401.2015.110523810.3109/21691401.2015.1105238 ↗
2. Bukowski RM. · Semin Urol Oncol · 2001 · 19 · 148
3. 10.1200/JCO.2006.08.541510.1200/JCO.2006.08.5415 ↗
4. 10.1200/JCO.2009.21.846110.1200/JCO.2009.21.8461 ↗
5. 10.1080/21691401.2016.119645610.1080/21691401.2016.1196456 ↗
6. 10.1080/21691401.2017.130455110.1080/21691401.2017.1304551 ↗
7. 10.1590/S1415-4757201100030000110.1590/S1415-47572011000300001 ↗
8. 10.7754/Clin.Lab.2015.15051810.7754/Clin.Lab.2015.150518 ↗
9. 10.18632/oncotarget.795310.18632/oncotarget.7953 ↗
10. 10.18632/oncotarget.823310.18632/oncotarget.8233 ↗
11. 10.1093/neuonc/nos00210.1093/neuonc/nos002 ↗
12. Si T · J Southern Med Univ · 2012 · 32 · 1568
13. 10.1038/nrm282210.1038/nrm2822 ↗
14. 10.1016/j.cellsig.2009.12.00110.1016/j.cellsig.2009.12.001 ↗
15. 10.1038/sj.bjc.660543710.1038/sj.bjc.6605437 ↗
16. 10.1182/blood-2006-12-06094710.1182/blood-2006-12-060947 ↗
17. 10.1016/j.urology.2009.10.03310.1016/j.urology.2009.10.033 ↗
18. 10.1186/1752-0509-4-5110.1186/1752-0509-4-51 ↗
19. 10.1002/jcb.2448710.1002/jcb.24487 ↗
20. WuZhang S · Tumor Biol · 2016 · 4 · 5193
21. 10.1038/srep0614510.1038/srep06145 ↗
22. 10.1016/j.febslet.2011.05.04210.1016/j.febslet.2011.05.042 ↗
23. 10.1158/1078-0432.CCR-11-171410.1158/1078-0432.CCR-11-1714 ↗
24. 10.1371/journal.pone.004674310.1371/journal.pone.0046743 ↗